TrianglePembrolizumab (NCT07021989)
Pembrolizumab trial for Hodgkin Lymphoma, Adult (NCT07021989). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with classic Hodgkin lymphoma that relapsed or resisted one doxorubicin-containing treatment line. Baseline tumor DNA must be measurable in blood. Prior stem-cell transplantation is excluded.
The idea: pembrolizumab supports immune attack while gemcitabine, vinorelbine and liposomal doxorubicin treat lymphoma. Blood tumor-DNA tests and PET scans guide later treatment. Selected responders can receive pembrolizumab and/or radiation without transplant; others may need salvage treatment and transplant assessment.
This phase 2 study plans 38 patients. Michael Spinner leads at the University of California, San Francisco, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.